LGM Pharma is a Daclizumab CAS# 152923-56-3 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
Questions? Call our customer API support number 1-(800)-881-8210.
LGM Pharma offers this active ingredient but not the finished dosage forms.
CAS No: 152923-56-3
AHFC code: 32:00.0
Synonyms: Dacliximab Daclizumab Humanized anti-TAC monoclonal antibody comprised of four subunits, two heavy chains and two light chains. All four chains are linked via disulfide bridges. The molecule contains approximately 2% carbohydrate by weight. The antibody belongs to the IgG1 subclass. The DNA sequence is 90% human origin and 10% mouse origin. The humanized anti-TAC is directed to the TAC receptor or high-affinity interleukin 2 receptor. Immunoglobulin G 1 (human-mouse monoclonal clone 1H4 gamma-chain anti-human interleukin 2 receptor), disulfide with human-mouse monoclonal clone 1H4 light chain, dimer. Molecular weight is approximately 150,000 daltons Immunoglobulin G 1 (human-mouse monoclonal clone 1H4 gamma-chain anti-human interleukin 2 receptor), disulfide with human-mouse monoclonal clone 1H4 light chain, dimer Ro 24-7375 UNII-CUJ2MVI71Y Zenapax Anti-IL-2 Humanized antiCD25 Ig gamma-1 chain C region
Zenapax is a humanized monoclonal antibody used for prevention of renal transplant rejection
Zenapax functions as an IL-2 receptor antagonist. Specifically it inhibits IL-2-mediated activation of lymphocytes, a critical pathway in the cellular immune response involved in allograft rejection.
Mode of Action:
Zenepax binds with high-affinity to the Tac subunit of the high-affinity IL-2 receptor complex and inhibits IL-2 binding. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes.
Most likely removed by opsonization via the reticuloendothelial system when bound to lymphocytes.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.
API’s From Quality Manufacturers:
Cost effective materials based on specific requirements
Small quantities for initial research and larger development quantities towards product commercialization
Technical packages, letters of access to filed DMFs